
Vip Patel
Examiner (ID: 14317, Phone: (571)272-2458 , Office: P/2879 )
| Most Active Art Unit | 2879 |
| Art Unit(s) | 2889, 2875, 2618, 2879, 2604, 3621, 2215 |
| Total Applications | 2443 |
| Issued Applications | 2199 |
| Pending Applications | 38 |
| Abandoned Applications | 210 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18434377
[patent_doc_number] => 20230181671
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => POLYPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/902449
[patent_app_country] => US
[patent_app_date] => 2022-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62578
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17902449
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/902449 | POLYPEPTIDES | Sep 1, 2022 | Pending |
Array
(
[id] => 18138905
[patent_doc_number] => 20230012740
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/929458
[patent_app_country] => US
[patent_app_date] => 2022-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22045
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17929458
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/929458 | Treatment of inflammatory conditions delivery of interleukin-1 receptor antagonist fusion protein | Sep 1, 2022 | Issued |
Array
(
[id] => 18297549
[patent_doc_number] => 20230107235
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => NOTCH3 Agonist Compositions and Methods for Treating Small Vessel Diseases
[patent_app_type] => utility
[patent_app_number] => 17/823824
[patent_app_country] => US
[patent_app_date] => 2022-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25990
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17823824
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/823824 | NOTCH3 Agonist Compositions and Methods for Treating Small Vessel Diseases | Aug 30, 2022 | Pending |
Array
(
[id] => 18793950
[patent_doc_number] => 11827702
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-28
[patent_title] => Anti-transferrin receptor antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/900161
[patent_app_country] => US
[patent_app_date] => 2022-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 22
[patent_no_of_words] => 41583
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17900161
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/900161 | Anti-transferrin receptor antibodies and uses thereof | Aug 30, 2022 | Issued |
Array
(
[id] => 18058008
[patent_doc_number] => 20220389094
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => Compositions and Methods for Treating Cancer with Anti-ROR1 Immunotherapy
[patent_app_type] => utility
[patent_app_number] => 17/820785
[patent_app_country] => US
[patent_app_date] => 2022-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29414
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -44
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17820785
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/820785 | Compositions and methods for treating cancer with anti-ROR1 immunotherapy | Aug 17, 2022 | Issued |
Array
(
[id] => 18267027
[patent_doc_number] => 20230088269
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => ANTI-IL-22R ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/819161
[patent_app_country] => US
[patent_app_date] => 2022-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32464
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17819161
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/819161 | ANTI-IL-22R ANTIBODIES | Aug 10, 2022 | Pending |
Array
(
[id] => 18036612
[patent_doc_number] => 20220380827
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN
[patent_app_type] => utility
[patent_app_number] => 17/881156
[patent_app_country] => US
[patent_app_date] => 2022-08-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9644
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17881156
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/881156 | METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN | Aug 3, 2022 | Abandoned |
Array
(
[id] => 19738343
[patent_doc_number] => 12215161
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-04
[patent_title] => Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
[patent_app_type] => utility
[patent_app_number] => 17/817295
[patent_app_country] => US
[patent_app_date] => 2022-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 49
[patent_figures_cnt] => 49
[patent_no_of_words] => 23097
[patent_no_of_claims] => 80
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 119
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17817295
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/817295 | Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies | Aug 2, 2022 | Issued |
Array
(
[id] => 18005014
[patent_doc_number] => 20220363780
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-17
[patent_title] => COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/815535
[patent_app_country] => US
[patent_app_date] => 2022-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24064
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17815535
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/815535 | Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof | Jul 26, 2022 | Issued |
Array
(
[id] => 18418525
[patent_doc_number] => 20230172983
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCERS
[patent_app_type] => utility
[patent_app_number] => 17/814434
[patent_app_country] => US
[patent_app_date] => 2022-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69489
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814434
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/814434 | Compositions and methods for treating CEACAM positive cancers | Jul 21, 2022 | Issued |
Array
(
[id] => 18181595
[patent_doc_number] => 20230042324
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => ANTI-GITR ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/812256
[patent_app_country] => US
[patent_app_date] => 2022-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28344
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17812256
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/812256 | ANTI-GITR ANTIBODIES AND USES THEREOF | Jul 12, 2022 | Pending |
Array
(
[id] => 17929804
[patent_doc_number] => 20220324929
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-13
[patent_title] => TARGETED MODIFIED TNF FAMILY MEMBERS
[patent_app_type] => utility
[patent_app_number] => 17/847380
[patent_app_country] => US
[patent_app_date] => 2022-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8337
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17847380
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/847380 | Targeted modified TNF family members | Jun 22, 2022 | Issued |
Array
(
[id] => 18196233
[patent_doc_number] => 20230049752
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 17/846900
[patent_app_country] => US
[patent_app_date] => 2022-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63875
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17846900
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/846900 | Claudin-6 antibodies and drug conjugates | Jun 21, 2022 | Issued |
Array
(
[id] => 18178848
[patent_doc_number] => 20230039577
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => ANTI-GITR ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/808248
[patent_app_country] => US
[patent_app_date] => 2022-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 122849
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17808248
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/808248 | ANTI-GITR ANTIBODIES AND METHODS OF USE THEREOF | Jun 21, 2022 | Abandoned |
Array
(
[id] => 18228763
[patent_doc_number] => 20230067757
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => ANTI-CLAUDIN 18 ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/846709
[patent_app_country] => US
[patent_app_date] => 2022-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36645
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17846709
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/846709 | ANTI-CLAUDIN 18 ANTIBODIES AND METHODS OF USE THEREOF | Jun 21, 2022 | Pending |
Array
(
[id] => 17930767
[patent_doc_number] => 20220325892
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-13
[patent_title] => APPARATUS AND METHOD FOR OOCYTE RESCUE IN VITRO POST STIMULATION
[patent_app_type] => utility
[patent_app_number] => 17/846845
[patent_app_country] => US
[patent_app_date] => 2022-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15867
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17846845
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/846845 | APPARATUS AND METHOD FOR OOCYTE RESCUE IN VITRO POST STIMULATION | Jun 21, 2022 | Abandoned |
Array
(
[id] => 18020627
[patent_doc_number] => 20220372126
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => ANTI CCL24 (EOTAXIN2) ANTIBODIES FOR USE IN THE TREATMENT OF HEPATIC DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/807801
[patent_app_country] => US
[patent_app_date] => 2022-06-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14194
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17807801
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/807801 | Anti CCL24 (eotaxin2) antibodies for use in the treatment of hepatic diseases | Jun 19, 2022 | Issued |
Array
(
[id] => 18529978
[patent_doc_number] => 20230235046
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => STABLE ANTI-CLEVER-1 ANTIBODY FORMULATION
[patent_app_type] => utility
[patent_app_number] => 18/001689
[patent_app_country] => US
[patent_app_date] => 2022-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10792
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 149
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001689
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/001689 | STABLE ANTI-CLEVER-1 ANTIBODY FORMULATION | Jun 13, 2022 | Pending |
Array
(
[id] => 18233417
[patent_doc_number] => 11597966
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-03-07
[patent_title] => Non-invasive diagnosis of graft rejection in organ transplant patients
[patent_app_type] => utility
[patent_app_number] => 17/836671
[patent_app_country] => US
[patent_app_date] => 2022-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 7
[patent_no_of_words] => 14749
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 191
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17836671
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/836671 | Non-invasive diagnosis of graft rejection in organ transplant patients | Jun 8, 2022 | Issued |
Array
(
[id] => 18486181
[patent_doc_number] => 20230213524
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => DIAGNOSTIC ASSAYS AND KITS FOR DETECTION OF FOLATE RECEPTOR 1
[patent_app_type] => utility
[patent_app_number] => 17/831254
[patent_app_country] => US
[patent_app_date] => 2022-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26942
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831254
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/831254 | DIAGNOSTIC ASSAYS AND KITS FOR DETECTION OF FOLATE RECEPTOR 1 | Jun 1, 2022 | Abandoned |